Hims & Hers Health, Inc. (NYSE:HIMS) Insider Patrick Harrison Carroll Sells 15,000 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Patrick Harrison Carroll sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $22.07, for a total transaction of $331,050.00. Following the transaction, the insider now owns 196,941 shares in the company, valued at $4,346,487.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Hims & Hers Health Trading Up 0.9 %

Shares of NYSE:HIMS opened at $23.62 on Friday. Hims & Hers Health, Inc. has a 52 week low of $6.58 and a 52 week high of $25.74. The company’s 50 day moving average is $18.57 and its two-hundred day moving average is $18.33. The company has a market cap of $5.07 billion, a PE ratio of 53.68 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same period in the prior year, the company posted ($0.04) earnings per share. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Institutional Trading of Hims & Hers Health

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 1.0% during the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares during the period. Renaissance Technologies LLC lifted its holdings in Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after acquiring an additional 3,205,108 shares during the period. Farallon Capital Management LLC boosted its holdings in Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after buying an additional 1,634,000 shares in the last quarter. Bank of New York Mellon Corp grew its position in Hims & Hers Health by 67.5% during the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after buying an additional 273,473 shares during the period. Finally, M&G Plc purchased a new position in Hims & Hers Health in the first quarter valued at about $8,232,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday. Needham & Company LLC initiated coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Bank of America increased their price target on shares of Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, October 21st. TD Cowen lifted their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Finally, Piper Sandler reissued a “neutral” rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $21.00.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.